- Home
- DMAC vs PHT Comparison
DMAC vs PHT Comparison
Compare DMAC & PHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- PHT
- Stock Information
- Founded
- DMAC 2000
- PHT 2002
- Country
- DMAC United States
- PHT United States
- Employees
- DMAC N/A
- PHT N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- PHT Investment Managers
- Sector
- DMAC Health Care
- PHT Finance
- Exchange
- DMAC Nasdaq
- PHT Nasdaq
- Market Cap
- DMAC 260.0M
- PHT 237.1M
- IPO Year
- DMAC N/A
- PHT N/A
- Fundamental
- Price
- DMAC $4.76
- PHT $8.06
- Analyst Decision
- DMAC Strong Buy
- PHT
- Analyst Count
- DMAC 4
- PHT 0
- Target Price
- DMAC $10.75
- PHT N/A
- AVG Volume (30 Days)
- DMAC 353.4K
- PHT 85.5K
- Earning Date
- DMAC 08-06-2025
- PHT 01-01-0001
- Dividend Yield
- DMAC N/A
- PHT 8.76%
- EPS Growth
- DMAC N/A
- PHT N/A
- EPS
- DMAC N/A
- PHT 0.98
- Revenue
- DMAC N/A
- PHT N/A
- Revenue This Year
- DMAC N/A
- PHT N/A
- Revenue Next Year
- DMAC N/A
- PHT N/A
- P/E Ratio
- DMAC N/A
- PHT $7.71
- Revenue Growth
- DMAC N/A
- PHT N/A
- 52 Week Low
- DMAC $3.19
- PHT $6.41
- 52 Week High
- DMAC $6.82
- PHT $7.60
- Technical
- Relative Strength Index (RSI)
- DMAC 64.04
- PHT 50.10
- Support Level
- DMAC $4.81
- PHT $7.99
- Resistance Level
- DMAC $5.60
- PHT $8.07
- Average True Range (ATR)
- DMAC 0.45
- PHT 0.05
- MACD
- DMAC 0.11
- PHT -0.01
- Stochastic Oscillator
- DMAC 67.90
- PHT 35.29
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.